| Regulatory Rapporteur October 2022 | MEMBERS |
| The importance of subjective and qualitative risk management for medical devices regulation | MEMBERS |
| Inclusion of older people in drug development and clinical trials: Part 2 | MEMBERS |
| EU expert panels for high-risk devices - another level of review? | MEMBERS |
| The health economics profile of new pharmaceuticals | MEMBERS |
| Navigating the MDR's heightened surveillance and performance requirements | MEMBERS |
| The new UK MDR - a great start to a long road ahead | MEMBERS |